A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes.
A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes.
复制标题
DOI：
10.1007/s10549-014-2944-4
复制
发表时间：
2014-06
影响因子：
3.8
通讯作者：
Schernhammer, Eva S.
中科院分区：
文献类型：
--
作者：
Chen, Wendy Y.;Giobbie-Hurder, Anita;Gantman, Kathryn;Savoie, Jennifer;Scheib, Rochelle;Parker, Leroy M.;Schernhammer, Eva S.
研究补充褪黑激素对绝经后乳腺癌幸存者睡眠、情绪和潮热的影响。在一项随机、双盲、安慰剂对照研究中，95名绝经后女性，既往有0-III期乳腺癌病史，已完成积极的癌症治疗（包括激素治疗），以1：1的比例随机分配至每天3 mg口服褪黑激素（n=48）或安慰剂（n=47），持续4个月。在基线和4个月时，分别使用匹兹堡睡眠质量指数（PSQI）、流行病学研究中心-抑郁症（CES-D）和中北部癌症治疗组（NCCTG）潮热日记，通过自填问卷评估睡眠、情绪和潮热。86名妇女（91%）完成了研究，并提供了前后问卷。在基线时，52%的参与者在入组前一个月报告睡眠不佳。与安慰剂组受试者相比，随机分配至褪黑激素组的受试者通过PSQI测量的主观睡眠质量显著改善，包括睡眠质量、日间功能障碍和总分领域。例如，安慰剂组PSQI评分的平均变化为-0.1，而褪黑素组为-1.9（p<0.001）。在抑郁或潮热的测量方面没有显著差异。睡眠障碍在乳腺癌幸存者中很常见，即使在完成积极的癌症治疗后。这是第一个在乳腺癌幸存者中进行的随机安慰剂对照研究，证明褪黑激素与主观睡眠质量的改善有关，没有任何显著的不良影响。
To examine the effects of melatonin supplementation on sleep, mood, and hot flashes in postmenopausal breast cancer survivors. In a randomized, double-blind, placebo-controlled study, 95 postmenopausal women with a prior history of stage 0-III breast cancer who had completed active cancer treatment (including hormonal therapy) were randomly assigned 1:1 to either 3 mg oral melatonin (n=48) or placebo daily (n=47) for 4 months. Sleep, mood, and hot flashes were assessed at baseline and four months via self-administered questionnaire using the Pittsburgh Sleep Quality Index (PSQI), Center for Epidemiologic Studies – Depression (CES-D), and the North Central Cancer Treatment Group (NCCTG) hot flash diary, respectively. Eighty-six women (91%) completed the study and provided pre and post questionnaires. At baseline, 52% of participants reported poor sleep in the month prior to enrollment. Compared to subjects on placebo, subjects randomized to melatonin experienced significantly greater improvements in subjective sleep quality as measured by the PSQI, including domains on sleep quality, daytime dysfunction and total score. For example, the mean change in PSQI score was −0.1 in the placebo group compared to −1.9 in the melatonin group (p<0.001). There were no significant differences in measures of depression or hot flashes. Sleep disturbances are common among breast cancer survivors, even after completion of active cancer treatment. This is the first randomized placebo-controlled study among breast cancer survivors to demonstrate that melatonin was associated with an improvement in subjective sleep quality, without any significant adverse effects.
登录
查看更多内容
影响因子：
1.9
作者：
Payne, Judith K.;Held, Joanne;Shaw, Heather
通讯作者：
Shaw, Heather
影响因子：
45.3
作者：
Berger, Ann M.;Kuhn, Brett R.;Agrawal, Sangeeta
通讯作者：
Agrawal, Sangeeta
影响因子：
3.8
作者：
Courneya, Kerry S.;Sellar, Christopher M.;Reiman, Tony
通讯作者：
Reiman, Tony
影响因子：
1.9
作者：
Epstein, Dana R;Dirksen, Shannon R
通讯作者：
Dirksen, Shannon R
影响因子：
105.7
作者：
Buscemi, N;Vandermeer, B;Baker, G
通讯作者：
Baker, G